Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Metabolism. 2023 Jun 28;146:155644. doi: 10.1016/j.metabol.2023.155644

Fig. 8. YTK-2205 exerts therapeutic efficacy in obesity and hepatosteatosis via p62.

Fig. 8.

(A) Injection timeline and details of YTK-1105 in HFD-induced obese murine model of p62−/− and +/+ mice. (B) Body weight changes during compound administration in p62−/− and +/+ mice. (left panel, n = 5). Percent body weight changes compared with baseline at the time of sacrifice (right panel, n = 5). (C) Weight of compound treated livers in p62−/− and +/+ mice (n = 5). (D) H & E staining (left panel) and TG levels (right panel, n = 5) of p62−/− and +/+ liver treated with YTK-2205 or vehicle. Scale bars, 50 μm. (E) WB of p62−/− and +/+ liver samples treated with YTK-2205 or vehicle. (F) IHC staining of LC3 in p62−/− and +/+ liver treated with YTK-2205 or vehicle. Scale bars, 50 μm (left column), 5 μm (right column).